Comparison of testosterone decanoate, drostanolone and testololactone in disseminated breast cancer--a randomized clinical study.
It can be said that a single hormone therapy with testosterone decanoate, drostanolone, and testosterone gave similar rates of objective responses in metastatic breast cancer. The presented randomized study has been done to prove whether an additional chemotherapy to hormone applications would further improve therapeutic results. During an observation period of 10 to 16 weeks testosterone decanoate and testolactone in combination with cyclophosphamide have more benefitial effects on the patients than drostanolone plus cyclophosphamide. The combination therapy augmented the rate of objective responses from 22-25 percent to 46-55 percent.
D000328:Adult; D000368:Aged; D000732:Androstanols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013738:Testolactone / Q000627:therapeutic use*; D013739:Testosterone / Q000627:therapeutic use*
D000732:Androstanols; D013739:Testosterone; D013738:Testolactone; D003520:Cyclophosphamide